Medtronic PLC vs Marathon Petroleum Corp — how do they compare? Medtronic PLC trades at $87.8 (market cap $109.38B), while Marathon Petroleum Corp trades at $462.2 (market cap $124.20B). The key difference: Medtronic PLC and Marathon Petroleum Corp are close in size by market cap, and Medtronic PLC pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Marathon Petroleum Corp for 54 Days on average.
| MDT | MPC | |
|---|---|---|
Market Cap | $109.38B | $124.20B |
Volume | 55,890,185 | 1,923,373 |
Sector | Health | Energy |
52-Week High | $105.35 | $463.34 |
52-Week Low | $73.75 | $162.63 |
Typical Hold Time | 63 Days | 54 Days |
Enterprise Value | $128.71B | $150.72B |
Dividend Yield | 3.37% | 0.9% |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.75, up 0.76% on the day, with strong analyst support (60.78% buy ratings) and a $97.80 consensus price target suggesting 11.4% upside. The stock shows consistent earnings beats in recent quarters with Q3 2026 results pending, while technical indicators signal bearish momentum despite oversold RSI readings. Recent positive developments include FDA clearances for new medical technologies and a 49-year dividend growth streak with a current 3.2% yield.
MDT presents a compelling value opportunity with reasonable valuation multiples (P/E 21.06, P/S 2.93) and improving fundamentals, though technical weakness and competitive pressures warrant caution. The company's revenue growth acceleration to $33.54B in 2025 and strong cash flow generation support the dividend sustainability, while debt levels have increased to 31.11% of assets, representing a key monitoring point for investors.
Marathon Petroleum (MPC) trades at $463.34, up 7.17% over 24 hours and near its 52-week high. The stock exhibits strong bullish momentum with consistent earnings beats and robust profitability metrics, including a 47.9% ROE. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export curbs pose a risk. Technical indicators show bullish moving averages but an overbought RSI, with key resistance at $452.
MPC presents a compelling investment case with solid fundamentals, high analyst buy ratings (75.76%), and a consensus price target of $420.30. Upside is driven by elevated refining margins and earnings growth, but risks include regulatory threats to exports and volatile energy markets. The stock's current premium to target suggests cautious optimism amid near-term overbought conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →